ReSearch Pharmaceutical Services (RPS), a US-based contract research organization (CRO) and Asklep, a Japanese CRO, have formed a new Joint Venture Company (JVC) to deliver R&D outsourcing solutions in Japan to the medical device and biopharmaceutical industries.
Under the RPS-Asklep exclusive collaboration, RPS will leverage its proprietary structures and global footprint to deliver customized solutions across large, mid-size and small and virtual organizations.
The collaboration will offer wide options for the industry ranging from embedded, hybrid, and full-service solutions, which will be available to clients using standard operating procedures, processes and systems.
RPS CEO and founder Daniel Perlman said the new collaboration will work with the combination of company's innovative approaches to meet the industry's needs with Asklep's excellent reputation, significant size, and local infrastructure.
"RPS will be positioned to meet current and future needs across the biopharmaceutical and medical device industries," Perlman added.
"Japan is an important market for clinical development and this JVC brings ownership and accountability with mutual success and long-term stability to the benefit of customers."
Asklep president and CEO Hiroshi Ichikawa said, "We are delighted to partner with RPS as it provides very unique solutions ranging from embedded, functional and cross-functional programs to enhanced global full-service solutions. Combining RPS' global solutions and Asklep's localized services, we believe the JVC will address an unmet need in Japan ."
